Amneal reports $796 million Q2 FY2026 revenue; raises 2026 guidance
AI Market Summary
Amneal reported strong Q2 FY2026 results with revenue up 10% and adjusted EPS up 20%, driven by Affordable Medicines and Specialty growth, alongside margin expansion and lower interest expense from debt repricing. Management raised full-year revenue, EBITDA, and EPS guidance and increased capex to expand injectables and women's health capacity. Near-term risks include an estimated $20m flood impact and potential biosimilar launch timing slippage.
Impact level
● Medium
Affected assets
NCSKS2USD/USDT+0.00%
AI Insight · NCSKS2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Amneal (AMRX) reported fiscal Q2 2026 revenue of $796 million, up 10% year over year, with adjusted EBITDA of $206 million, up 12%. Adjusted EPS rose 20% to $0.30 as profitability improved and interest expense declined. By segment, Affordable Medicines revenue increased 13% to $490 million and Specialty revenue climbed 17% to $149 million, while AvKARE revenue fell 4% to $157 million.
